ScholarIQanswers from OpenAlex & ORCID
Theodore W. Laetsch
ResearcherPublications, citations & collaboration network
Theodore W. Laetsch is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Theodore W. Laetsch have?
ScholarIQindexed works
Theodore W. Laetsch has 382 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Theodore W. Laetsch have?
ScholarIQcitation count
Theodore W. Laetsch has 18,586 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Theodore W. Laetsch?
ScholarIQh-index
Theodore W. Laetsch has an h-index of 48 in OpenAlex.
What is the i10-index of Theodore W. Laetsch?
ScholarIQi10-index
Theodore W. Laetsch has an i10-index of 134 in OpenAlex.
What is the ORCID of Theodore W. Laetsch?
ScholarIQorcid
The ORCID for Theodore W. Laetsch is on the source record.
What is the OpenAlex record for Theodore W. Laetsch?
ScholarIQopenalex
The OpenAlex for Theodore W. Laetsch is on the source record.
What are the most-cited papers on Theodore W. Laetsch?
ScholarIQmost cited works
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
Shannon L. Maude, Theodore W. Laetsch, Jochen Buechner, Susana Rives, Michael Boyer, Henrique Bittencourt, Peter Bader, Michael R. Verneris, Heather E. Stefanski, Gary D. Myers, Muna Qayed, Barbara De Moerloose, Hidefumi Hiramatsu, Krysta Schlis, Kara L. Davis, Paul L. Martin, Eneida R. Nemecek, Gregory A. Yanik, Christina Peters, André Baruchel, Nicolas Boissel, Françoise Méchinaud, Adriana Balduzzi, Joerg Krueger, Carl H. June, Bruce L. Levine, Patricia A. Wood, Tetiana Taran, Mimi Leung, Karen T. Mueller, Yiyun Zhang, Kapildeb Sen, David Lebwohl, Michael A. Pulsipher, Stephan A. Grupp
Efficacy of Larotrectinib in <i>TRK</i> Fusion–Positive Cancers in Adults and Children
Alexander Drilon, Theodore W. Laetsch, Shivaani Kummar, Steven G. DuBois, Ulrik Lassen, George D. Demetri, Michael J. Nathenson, Robert C. Doebele, Anna F. Farago, Alberto S. Pappo, Brian Turpin, Afshin Dowlati, Marcia S. Brose, Leo Mascarenhas, Noah Federman, Jordan Berlin, Wafik S. El‐Deiry, Christina S. Baik, John F. Deeken, Valentina Boni, Ramamoorthy Nagasubramanian, Matthew H. Taylor, Erin R. Rudzinski, Funda Meric‐Bernstam, Davendra Sohal, C. Patrick, Luis E. Raez, Jaclyn F. Hechtman, Ryma Benayed, Marc Ladanyi, Brian B. Tuch, Kevin Ebata, Scott Cruickshank, Nora Ku, Michael C. Cox, Douglas S. Hawkins, David S. Hong, David M. Hyman
Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials
David S. Hong, Steven G. DuBois, Shivaani Kummar, Anna F. Farago, Catherine M. Albert, Kristoffer Staal Rohrberg, Cornelis M. van Tilburg, Ramamoorthy Nagasubramanian, Jordan Berlin, Noah Federman, Leo Mascarenhas, Birgit Geoerger, Afshin Dowlati, Alberto S. Pappo, Stefan Bielack, François Doz, Ray McDermott, Jyoti D. Patel, Russell J. Schilder, Makoto Tahara, Stefan M. Pfister, Olaf Witt, Marc Ladanyi, Erin R. Rudzinski, Shivani Nanda, Barrett H. Childs, Theodore W. Laetsch, David M. Hyman, Alexander Drilon
Three-Year Update of Tisagenlecleucel in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia in the ELIANA Trial
Theodore W. Laetsch, Shannon L. Maude, Susana Rives, Hidefumi Hiramatsu, Henrique Bittencourt, Peter Bader, André Baruchel, Michael Boyer, Barbara De Moerloose, Muna Qayed, Jochen Buechner, Michael A. Pulsipher, Gary Douglas Myers, Heather E. Stefanski, Paul L. Martin, Eneida R. Nemecek, Christina Peters, Gregory A. Yanik, Seong Lin Khaw, Kara L. Davis, Joerg Krueger, Adriana Balduzzi, Nicolas Boissel, Ranjan Tiwari, Darragh O’Donovan, Stephan A. Grupp